GSK to buy food allergy drug maker RAPT in $2.2bn deal

US-based biotech firm is developing treatment for allergies to nuts, milk and eggs in children and adults Business live – latest updates GSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn (£1.6bn) deal to acquire a Californian biotech company which is developing a drug to protect against severe food allergies, including allergies to nuts, milk and eggs. It is the first large deal announced by GSK’s new chief executive, Luke Miels , who joined the London-based company in 2017 as chief commercial officer and took the reins from Emma Walmsley at the start of the year. Continue reading…